Clinical trial
A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck
NCT01044433 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- March 3, 2017
- Enrollment
- 44 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck cancer, metastatic squamous neck cancer with occult primary squamous cell carcinoma, recurrent metastatic squamous neck cancer with occult primary, recurrent salivary gland cancer, recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, recurrent verrucous carcinoma of the larynx, recurrent verrucous carcinoma of the oral cavity, salivary gland squamous cell carcinoma, stage iv salivary gland cancer, stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the larynx, stage iv squamous cell carcinoma of the lip and oral cavity, stage iv squamous cell carcinoma of the oropharynx, stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iv verrucous carcinoma of the larynx, stage iv verrucous carcinoma of the oral cavity